A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Lupin Limited partners with SteinCares to license and supply ranibizumab in Latin America, excluding Mexico and Argentina.

Nipocalimab-aahu is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds with high affinity to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...

Lupin and SteinCares ink license and supply agreement for ranibizumab in Latin America: Our Bureau, Mumbai Monday, May 26, 2025, 14:10 Hrs [IST] Global Pharma major Lupin Limited ...

Belrestotug, a human IgG1 antibody created to bind with high-affinity T ... Both trials were investigating the drug in combination with the PD-1 monoclonal antibody Jemperli (dostarlimab). However, ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.

Lupin has entered into a licence agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin ...